Mizuho Reiterates Buy Rating on HAE, Sets $85 Target
Mizuho maintains its positive outlook on HAE with a buy rating and an $85 price target, a 8.70% upside from the current price.
Key Points
- Mizuho reiterated its buy rating on HAE, setting a price target of $85 on June 15, 2026.
- Mizuho's $85 price target implies 8.70% upside from Haemonetics Corporation's ($HAE) current $78.20 share price.
- HAE shares are trading near $78.2, with recent insider activity including sales by executives in June.
- Peer funds like BlackRock and Neuberger Berman adjusted their HAE positions, reflecting varied institutional sentiment.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has reiterated its buy rating on HAE, setting a new price target of $85 as of June 15, 2026. This indicates continued confidence in HAE's performance, with Mizuho analyst Anthony Petrone leading the coverage.
Other Institutional Activity in HAE
Institutional investors have been active in HAE recently. BlackRock, Inc. reduced its holdings by 200,975 shares, now owning 5,619,979 shares valued at about $316.7 million. Neuberger Berman Group LLC also trimmed its position by 304,758 shares, holding 3,560,918 shares worth around $200.6 million. In contrast, AQR Capital Management LLC increased its stake by 193,439 shares, bringing its total to 3,356,543 shares valued at approximately $185.7 million. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated positions, with 2,559,316 and 2,090,389 shares respectively.
Haemonetics Corporation Stock Down 24.8%
Shares of HAE are trading near $78.2. The stock has experienced a range of institutional buying and selling, reflecting diverse opinions on its future performance.
$HAE price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Haemonetics Corporation
Recent insider transactions include sales by Maryanne Maunsell, VP and Chief Accounting Officer, who sold 259 shares on June 5, 2026, at an average price of $71.28. Laurie Miller, SVP of Human Resources, also sold 313 shares on the same date. Earlier, on May 15, 2026, James Darecca, EVP and CFO, bought 29,312 shares, indicating some insider confidence in the company's prospects.
Analysts Set New Price Targets
On June 15, 2026, Mizuho maintained its buy rating on HAE with a price target of $85. Previously, B of A Securities upgraded HAE to a buy with an $80 target on May 22, 2026. Barrington Research maintained a buy rating with a higher target of $89 on May 12, 2026. The current consensus among analysts is a buy rating, with a mean target price reflecting optimism about HAE's potential growth.
Bottom Line
Mizuho's reiterated buy rating and $85 price target suggest confidence in HAE's future prospects. Investors and analysts are keeping a close eye on HAE, especially after recent insider transactions and varied institutional activity. As always, these ratings and targets reflect past analyses and do not guarantee future performance.
Get Haemonetics Corporation alerts
New 13F filings, insider trades, and analyst moves on $HAE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.